BIO: Biotech cheering can't drown out industry fears

As a story in the Star-Telegram aptly notes, it's a bullish biotech industry that's meeting at BIO 2007. Ernst & Young called 2006 the "year of the deal [1]" while industry leaders like Steven Burrill are referring to "our finest hour." But there's a dark ring around the silver cloud. Consumers are angry at the prices being charged for new drugs [2] and investors have been far less excited about biotech companies than the big pharma companies doing deals with them. And if those big pharma wallets close, biotech could be singing a more plaintive tune at future gatherings.

- read the report [3] from the New Jersey Star-Telegram

ALSO: E&Y crunched the numbers of public biotech companies to come up with a new ranking of biotech clusters around the U.S. San Francisco came in first, followed by New England, San Diego and New Jersey. They were followed by the Mid-Atlantic region and the Southeast, which have a far higher concentration of smaller, private developers. Report [4]

Related Articles:
Generic legislation threatens biotech. Report [5]
BIO outlines most prominent industry threats. Report [6]